A ngiogenesis, the formation of new blood vessels from preexisting capillaries, is a tightly regulated process and normally does not occur, except during developmental and wound repair processes.
1 This strict regulation is manifested by a balanced production of proangiogenic and antiangiogenic factors that keep angiogenesis in check.
1 However, this balance between proangiogenic and antiangiogenic factors abrogates under many pathologic conditions, including cancer, diabetes, age-related macular degeneration, and retinopathy of prematurity, resulting in the growth of abnormal new blood vessels. [2] [3] [4] Vascular endothelial growth factor (VEGF) is a major proangiogenic factor that promotes the growth of new blood vessels under ischemic conditions. VEGF stimulates endothelial cell proliferation, migration, and survival. When retinal pigment epithelial cells begin to wither because of lack of nutrition (ischemia), VEGF goes into action to create neovascularization, and it acts as a restorative function in other parts of the body. In the retina, these vessels do not form properly and leak, ultimately resulting in retinal detachment and loss of vision. Recently, several antiangiogenic compounds have been shown to inhibit neovascularization and prevent bleeding into the vitreous by inhibiting VEGF binding to its receptors on endothelial cells. 5, 6 Therefore, there is significant interest in the development and identification of molecules that can inhibit the growth of new blood vessels.
Vascular basement membrane (VBM) constitutes an important component of blood vessels. 7 Remodeling of VBM can provide crucial proangiogenic and antiangiogenic molecules to control the formation of new capillaries. 8 -10 Type IV collagen is a major component of VBM and plays a crucial role in the regulation of angiogenesis. 7 Proteolytic degradation of type IV collagen in the VBM generates antiangiogenic molecules. 11 One such antiangiogenic molecule, derived from the ␣1 chain of type IV collagen noncollagenous (NC1) domain, ␣1(IV)NC1 (arresten), has been tested in mice against a variety of cancers. 12, 13 However, the molecular and cellular mechanisms responsible for the inhibition of angiogenesis require further delineation. In vitro and in vivo studies have demonstrated that ␣1(IV)NC1 can directly affect endothelial cell migration and impact their proliferation and sprouting. 13 However, the effects of ␣1(IV)NC1 on retinal endothelial cell function and vascularization have not been previously studied.
In the present study, we demonstrate that ␣1(IV)NC1 is a potent inhibitor of mouse retinal endothelial cell (MREC) proliferation, migration, and tube formation in vitro and angiogenesis in vivo. We demonstrate that ␣1(IV)NC1 promotes apoptosis through the activation of caspase-3 and PARP cleavage, presumably by inhibiting FAK/p38-mitogen-activated protein kinase (MAPK)/Bcl-2 and Bcl-x L signaling cascades in MREC without affecting mouse retinal pigment epithelial (MRPE) cells. These findings contribute significantly to our understanding of the apoptotic signaling mechanism and therapeutic potential of the ␣1(IV)NC1 molecule in retinal diseases with a neovascular component.
METHODS Preparation and Culture of Primary Mouse Retinal Endothelial and Retinal Pigment Epithelial Cells
All experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Primary MRECs were prepared and maintained as described previously. 14 MRECs were maintained in 40% HAM F-12, 40% DME-low glucose, 20% FCS supplemented with heparin (50 mg/L), endothelial mitogen (50 mg/L), L-glutamine (2 mM), penicillin/streptomycin (100 U/mL each), Na pyruvate (2.5 mM), NEAA (1ϫ), and 5 g/L murine IFN-␥ and were cultured on 0.8% gelatin-coated plates at 33°C with 5% CO 2 . MRPE cells were maintained in DMEM containing 10% FCS and 100 U/mL antibiotic and antimycotic solutions at 37°C with 5% CO 2 .
Proliferation Assay
A suspension of 40 ϫ 10 3 MRECs/well was used in the proliferation assay. MREC medium (500 L/well) was added to 24-well plates precoated with 10 g/mL type IV collagen. After 24 hours, that medium was replaced with MREC medium containing 10 ng/mL VEGF, and different concentrations of baculovirus expressed recombinant ␣1(IV)NC1 or ␣3(IV)NC1 (tumstatin) (0.5 and 1.0 M). 
Cell Viability Assay
The viability of MRECs and MRPE cells was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay (MTT) according to the manufacturer's protocols. Overnight serum-starved MRECs or MRPE cells (7.0 ϫ 10 3 /well) were plated on a 96-well plate and stimulated with VEGF (10 ng/mL)-containing medium. The next day, different concentrations of ␣1(IV)NC1 (0.25-1.0 M) were added and incubated for 24 hours. Apoptosis was monitored by trypan blue exclusion using the cell death detection ELISA kit.
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Migration Assay
MRECs (1.0 ϫ 10 4 /well) were seeded in no-serum medium with and without recombinant ␣1(IV)NC1. Medium containing 10 ng/mL VEGF was placed in the bottom wells of the Boyden chamber and incubated for 24 hours at 37°C with 5% CO 2. The numbers of MRECs that migrated and attached to the bottom side of the membrane were counted.
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Tube Formation Assay
Briefly, approximately 250 L basement membrane matrix (BMM; Matrigel; BD Biosciences, San Jose, CA) was added to each well of a 24-well plate and allowed to harden for 30 minutes at 37°C. A suspension of 50 ϫ 10 3 MRECs in medium without antibiotic was plated on top of the BMM-coated wells. The MRECs were stimulated with VEGF for tube stabilization and incubated with and without ␣1(IV)NC1 for 24 hours at 37°C and viewed under a microscope (CK2; Olympus, Tokyo, Japan).
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Scratch Wound Assays
Briefly, MREC wound assays were conducted in type IV collagencoated six-well tissue culture plates. MRECs were cultured to subconfluence, and wounds were created at the center of each plate by scraping the monolayer with a sterile pipette tip. 19 Medium containing 1 M ␣1(IV)NC1 was added only to experimental wells, and cells migrating to the wound area were monitored microscopically for 36 hours. Photographs were taken at different times, and migrated cells were counted in control and in ␣1(IV)NC1-treated wells.
Caspase-3, -8, and -9 Activity Assays
MRECs and MRPE cells were grown to subconfluence; cells detached and were plated at 0.5 ϫ 10 6 cells/well in a six-well plate (precoated with type IV collagen 10 g/mL) in 10% FCS-supplemented medium overnight. The following day, serum-containing medium was replaced with serum-free medium and incubated overnight at 37°C. Cells were then stimulated with VEGF (10 ng/mL) in MREC medium containing ␣1(IV)NC1 (1 M) and were incubated for 24 hours. TNF-␣ (80 ng/mL) was used as a positive control for caspase-3-dependent apoptosis, whereas staurosporine (50 nM) was used as a positive control for mitochondrial caspase-dependent apoptosis. A specific inhibitor of caspase-3, DEVD-fmk (20 M), was used to confirm the specificity of the assay. Similarly, caspase-8 and -9 inhibitors z-IEPD-fmk and z-LEHDfmk (20 M) were used. After 24 hours, the floating cells were collected, combined with the adherent cells, and washed three times with sterile PBS. Equal numbers of cells in each condition were resuspended and mixed in appropriate peptide substrate reaction buffers containing 100 mM HEPES, pH 7.0, (for caspase-3 and -8) and 100 mM MES, pH 6.5, (for caspase-9) in 30 L PBS and were transferred to a 96-well plate for fluorometric analysis in a microplate reader. Caspase-3, -8 and -9 activities were determined fluorometrically by cleavage of cellular substrate DEVD-AMC, IEPD-AMC, or LEHD-AFC, as described.
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FACS Analysis of MREC Incubated with ␣1(IV)NC1
Apoptotic and viable MRECs were measured by quantitative fluorescence analysis performed using fluorescence-activated cell sorting (FACS). Briefly, MRECs were incubated with and without ␣1(IV)NC1 (1 M) for 15 minutes at room temperature and were plated onto type IV collagen-coated 10-cm tissue culture plates containing VEGF (10 ng/ mL). The culture plates were incubated at 37°C with 5% CO 2 for 24 hours and were used for FACS analysis. Floating MRECs were collected, combined with adherent cells, removed by trypsinization (0.05% [wt/ vol] trypsin in 0.02% [wt/vol] EDTA), incubated for 5 minutes at 37°C, and washed twice with PBS, and the cell pellet was resuspended in 1ϫ binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 2.5 mM CaCl 2 ). In each condition, MRECs were suspended in binding buffer containing fluorescein isothiocyanate (FITC)-conjugated annexin-V and propidium iodide (PI) and were incubated for 20 minutes at room temperature in the dark. Additional binding buffer was added, and 10,000 events were acquired and analyzed by FACS.
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Cell Signaling Experiments
For FAK and p38-MAPK signaling experiments, approximately 1.0 ϫ 10 6 serum-starved MRECs or MRPE cells were preincubated for 10 minutes with ␣1(IV)NC1 (1 M), followed by VEGF (10 ng/mL) stimulation, and were seeded into 10-cm 2 dishes coated with type IV collagen (10 mg/mL) for different time intervals. Cells were lysed in RIPA lysis buffer, and extracts were analyzed by SDS-PAGE and immunoblotting with antibodies specific to phosphorylated and total FAK or p38-MAPK. 13, 18 For measuring caspase-3 activation, MRECs were incubated with ␣1(IV)NC1 for 6 to 24 hours at 37°C. Floating and adherent cells were pooled and lysed, and cytosolic extracts were immunoblotted. Cleaved activated caspase-3 was identified by specific monoclonal antibodies and with the use of an ECL detection kit.
Effect of ␣1(IV)NC1 on p38-MAPK-Dependent Bcl-2/Bcl-x L Regulation and Caspase-3/PARP Activation
Approximately 1 ϫ 10 6 serum-starved MRECs were collected and suspended in serum-free medium containing VEGF (10 ng/mL). These cells were pretreated with ␣1(IV)NC1 (1 M) or p38-MAPK specific inhibitor SB203580 (20 M) or TNF-␣ (80 ng/mL) for approximately 10 minutes and were seeded on type IV collagen precoated 10-cm 2 dishes for 24 hours. Plates were washed once with cold PBS, and cells were lysed on ice in RIPA lysis buffer and centrifuged at 4°C for 30 minutes at 13000 rpm. Approximately 30 g cytosolic extract/lane was separated using 10% SDS-PAGE, followed by immunoblotting with anti-Bclx L , Bcl-2, caspase-3, and PARP antibodies. Immunoreactivity of Bcl-x L , Bcl-2 proteins, cleaved caspase-3, and PARP were visualized with the ECL detection kit.
BMM Plug Assay
Fifteen male 12-week-old 129/Sv mice were used for this study. For each condition, three mice or six BMMs were used. All animal studies were reviewed and approved by the animal care and use committee of Boys Town National Research Hospital. BMM was injected subcutaneously into the right and left sides of mice, lateral to the abdominal midline. Control groups received only heparin in the BMM, whereas positive control groups received heparin and VEGF (100 ng/mL) with and without type IV collagen (10 g/mL). The experimental group received two different doses of ␣1(IV)NC1 (0.5 and 1 M) along with heparin and VEGF in the BMM. 22 After 10 days, mice were killed, and half the BMM plugs were fixed in 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin. The numbers of blood vessels from 12 high-power fields were counted. The other half of the BMM plugs were dispersed in sterile PBS and incubated at 4°C overnight. Hemoglobin levels were determined with Drabkin reagent.
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Statistical Analysis
Each experiment was performed three times and values are expressed as mean Ϯ SEM. Statistical analysis based on the Student's t-test (unilateral and unpaired) was scored to identify significant differences in multiple comparisons. P Ͻ 0.05 was considered statistically significant.
RESULTS
Distinct Antiangiogenic Activities of ␣1(IV)NC1
on MRECs ␣1(IV)NC1 was discovered as an antiangiogenic molecule with significant antitumor activities.
13 ␣1(IV)NC1 is liberated from the noncollagenous (NC1) domain of the ␣1 chain of type IV collagen by matrix metalloproteinase-9 (MMP-9). 23 The present studies were aimed at achieving an understanding the molecular mechanisms underlying angiogenesis inhibition by ␣1(IV)NC1 and its implications in the treatment of cancer and were conducted in an attempt to determine the antiangiogenic actions of ␣1(IV)NC1 in MRECs.
A series of angiogenesis experiments was conducted to determine the antiangiogenic activity of ␣1(IV)NC1 using MRECs and MRPE cells. VEGF is a major proangiogenic factor responsible for most ocular angiogenesis driven by ischemia. We first determined VEGF-stimulated antiangiogenic activity of ␣1(IV)NC1 by measuring MREC proliferation. We used [ 3 H]-thymidine incorporation to examine the antiproliferative effect of ␣1(IV)NC1. VEGF-stimulated proliferation of MRECs was significantly inhibited by ␣1(IV)NC1 in a concentration-dependent manner compared with ␣3(IV)NC1. The graph summarizes relative [ 3 H]-thymidine incorporation in MRECs incubated with ␣1(IV)NC1 and ␣3(IV)NC1 (␣1(IV)NC1 70.49% vs. ␣3(IV)NC1 50.49% at 1 m; Fig. 1A ). We also confirmed that MREC proliferation was inhibited dose dependently by ␣1(IV)NC1 with the use of methylene blue staining (Fig. 1B) . Such proliferation inhibition ([ 3 H]-thymidine incorporation or methylene blue staining) was not observed in MRPE cells incubated with ␣1(IV)NC1 (data not shown). Further, we tested antiangiogenic activity at different doses of ␣1(IV)NC1 (0, 0.25, 0.5, 0.75, and 1.0 M) by MTT cell viability assay after VEGF stimulation in MRECs. The results showed that MREC proliferation was increased significantly by VEGF stimulation, which was inhibited by ␣1(IV)NC1 dose dependently after 24 hours (Fig. 1C) . Interestingly, ␣1(IV)NC1 had no significant effect on MRPE cell proliferation in the presence of VEGF, indicating the endothelial cell-specific action of ␣1(IV)NC1 (Fig. 1D) .
The migration of endothelial cells is fundamentally important during angiogenesis. 13, 24 MREC migration across a collagen type IV-coated membrane toward VEGF in a Boyden chamber was significantly inhibited by ␣1(IV)NC1 in a dosedependent manner (0, 0.25, 0.5, and 1.0 M; Figs. 2A, B) . We further confirmed the antiangiogenic activity of ␣1(IV)NC1 by a functional assay of VEGF-mediated, stabilized MREC tube formation. 17 Tube formation on BMM is associated with endothelial cell migration and survival. 25 Incubation of MREC with ␣1(IV)NC1 inhibited VEGF-stabilized tube formation on BMM in a dose-dependent manner (Fig. 3A, ␣1(IV)NC1) . Our previous report states that the antiangiogenic activity of ␣1(IV)NC1 is mediated through ␣1␤1 integrin. 13 Interestingly, we observed that MRECs, when incubated with ␣1(IV)NC1 (1.0 M), becomes rounded (apoptosis like) and detaches from the BMM, forming clumps of cells (Fig. 3A, lower right corner) . This is perhaps caused by activation of the apoptosis in MRECs incu- 
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bated with ␣1(IV)NC1. The number of tubes formed after 36 hours in the presence of different doses of ␣1(IV)NC1 from three independent experiments is shown in Figure 3B . The decrease in the proliferation of MRECs incubated with ␣1(IV)NC1 was associated with a significant reduction in the migration of these cells. Consistent with the reduced proliferation and migration of MRECs incubated with ␣1(IV)NC1 on type IV collagen, we also observed the attenuation of MREC migration in scratch wound assays (Fig. 4A, ␣1(IV)NC1) . In addition, we observed apoptotic MRECs during incubation with ␣1(IV)NC1. Prolonged incubation of MRECs with ␣1(IV)NC1 resulted in their rounding and detachment from the matrix, indicating the onset of apoptotic events. Moreover, the number of adherent MRECs decreased, and floating cells increased compared with control cells, suggesting that cell detachment was caused by the presence of ␣1(IV)NC1. The average number of migrated MRECs into the scratch wound at different times with and without ␣1(IV)NC1 treatment in three independent experiments is shown in Figure 4B .
Impairment of In Vitro Apoptotic Activity of ␣1(IV)NC1 by Caspase Inhibitors
In tracing the signaling mechanisms involved in the rapid impairment of cell proliferation that precedes the loss of MREC viability and the irreversible commitment to cell death on incubation with ␣1(IV)NC1, we identified that ␣1(IV)NC1 induces apoptosis in MRECs (Fig. 5A) . To study whether caspase-3 could be activated by ␣1(IV)NC1, we incubated MRECs with ␣1(IV)NC1 and observed the activation of caspase-3 (Fig. 5A) . Caspase-3 is a pivotal molecule mediating cellular apoptosis. 26 If this activation of caspase-3 by ␣1(IV)NC1 is necessary for cellular apoptosis, a caspase-3-specific inhibitor should abolish ␣1(IV)NC1-induced apoptosis in MRECs. The incubation of MRECs with z-DEVD (a specific caspase-3 inhibitor) showed complete suppression ␣1(IV)NC1-induced cellular apoptosis and inhibition of caspase-3 activity (Fig. 5A, ␣1(IV)NC1ϩDEVD) . Similar apoptotic caspase-3 activation was not observed in MRPE cells incubated with ␣1(IV)NC1 (Fig. 5B, ␣1(IV)NC1) . These results suggest that the proapoptotic action of ␣1(IV)NC1 through the activation of caspase-3 is specific to MRECs.
We further evaluated whether ␣1(IV)NC1 induces the activation of upstream caspases such as caspase-8 and -9. We treated MRECs with ␣1(IV)NC1 and observed the activation of caspase-8 and -9 (Figs. 5C, D) . If this activation of caspase-8 and -9 by ␣1(IV)NC1 plays a role in cellular apoptosis, specific inhibitors should abolish ␣1(IV)NC1-induced caspase-8 and -9 activities in MRECs. Incubation of MRECs with z-IEPD-fmk and z-LEHD-fmk (specific caspase-8 and -9 inhibitors) showed the suppression of ␣1(IV)NC1-induced cellular apoptosis and the 
FACS Analysis of MREC Apoptosis by ␣1(IV)NC1
We further investigated the activation of apoptosis in MRECs incubated with and without ␣1(IV)NC1 with the use of FACS analysis. We quantified cellular apoptosis by measuring propidium iodide staining versus annexin V-FITC content in MRECs. MRECs incubated with control medium containing VEGF showed greater than 90% cell viability, whereas apoptosis was observed in less than 10% of total cell population (Fig.  6A ). The addition of ␣1(IV)NC1 under similar conditions decreased MREC viability to 26%, indicating that approximately 74% of cells underwent apoptosis (Fig. 6B) . Comprehensive statistical results of the observed apoptotic and nonapoptotic MRECs (incubated with and without ␣1(IV)NC1) are summarized in Figure 6C . Among the known caspases, caspase-3 is an important effector molecule for most cellular apoptosis. 26 To study whether caspase-3 could be activated by ␣1(IV)NC1, we incubated MRECs with ␣1(IV)NC1 for different time periods and observed the activation of caspase-3 in a time-dependent manner (Fig. 6D, lower blot) . The time-dependent activation of caspase-3 band intensities is shown in Figure 6D (upper graph).
Specific Apoptotic Effects of ␣1(IV)NC1 on p38-MAPK Signaling in Regulation of Bcl-2/Bcl-x L and Caspase-3/PARP Activation in MRECs
In this study we investigated whether ␣1(IV)NC1 played a role in the activation of caspase-3-mediated MREC apoptosis through the inactivation of p38-MAPK pathway. The p38-MAPK pathway is an important downstream target of FAK that is critical for the regulation of endothelial cell migration. 27, 28 FIGURE 4. Impaired migration and proliferation of MRECs incubated with ␣1(IV)NC1 in a scratch wound assay. (A) MRECs were cultured to 80% confluence in 24-well plates in serum-containing medium. Wounds were created in the MREC monolayer using a sterile pipette tip. Photographs were taken immediately and later at indicated time intervals after the wounds were created. Data are from one representative experiment. Similar results were obtained in two independent experiments. (B) Bar diagram represents quantification of the woundhealing assessment from duplicate wells of three independent experiments (n ϭ 6). *P Ͻ 0.001 for control versus ␣1(IV)NC1-treated MRECs. 
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Mice deficient in FAK display severely impaired vasculogenesis and cell migration, whereas overexpression significantly increases the migratory capacity of cells through activation of the MAPK pathway. 29, 30 These findings suggest that type IV collagen integrins/FAK/p38-MAPK pathway may play a major role in the regulation of matrix-mediated migration. Attachment of VEGF-treated MRECs to type IV collagen activated the FAK/p38 pathway (data not shown). Pretreatment of MRECs with ␣1(IV)NC1 did not inhibit the expression of FAK or p38-MAPK but significantly blocked the sustained phosphorylation of FAK and p38-MAPK (Figs. 7A, C, top panels) . In endothelial cells, VEGF-induced migration and cytoskeletal reorganization are mediated by ERKs-MAPK, whereas the expression of integrins and proteases is regulated by p38-MAPK. 31, 32 In contrast, the incubation of MRPE cells with ␣1(IV)NC1 had no effect on the phosphorylation of FAK or p38-MAPK on type IV collagen matrix, suggesting that ␣1(IV)NC1-induced signaling is specific to endothelial cells (Figs. 7B, D, upper panel) .
To understand whether the p38-MAPK pathway is involved in the proapoptotic activity of ␣1(IV)NC1, we examined changes in the expression of proapoptotic (Bax) and antiapoptotic (Bcl-2, Bcl-x L ) proteins in MRECs treated with ␣1(IV)NC1. ␣1(IV)NC1-treated MRECs did not show any effect on Bax expression (data not shown), whereas Bcl-x L expression and Bcl-2 expression were significantly inhibited at 24 hours (Fig.  7E , lane 2 vs. lane 1). Earlier we reported that ␣1(IV)NC1 regulates HIF-1␣ expression dependent on p38-MAPK. 13 Here, we evaluated whether ␣1(IV)NC1-regulated Bcl-2 and Bcl-x L expressions were mediated through p38-MAPK. A specific p38-MAPK inhibitor, SB203580, should inhibit Bcl-2 and Bcl-x L expression; treatment of MRECs with SB203580 showed the inhibition of Bcl-2 and Bcl-x L , confirming that expression of these antiapoptotic molecules in MRECs by ␣1(IV)NC1 is dependent on p38-MAPK (Fig. 7E, lane 3) . This is consistent with p38-MAPK-mediated endothelial cell apoptosis through the downregulation of Bcl-x L and Bcl-2. 33 Here, we also identified that activation of caspase-3 and PARP cleavage downstream of Bcl-2/Bcl-x L in MRECs treated with ␣1(IV)NC1 was p38-MAPK dependent (Fig. 7F, lane 2 vs. lane 1) . In addition treatment of MRECs with p38-MAPK inhibitor (SB203580) showed the activation of caspase-3 and PARP cleavage, further confirming that inactivation of the p38-MAPK pathway by ␣1(IV)NC1 had an impact on MREC apoptosis (Fig. 7E, lane 3) .
Regulation of VEGF-Induced Neovascularization by ␣1(IV)NC1
DISCUSSION
The NC1 domain generated from type IV collagen ␣1 chain ␣1(IV)NC1 was identified as an antiangiogenic molecule, and its activity was mediated through ␣1␤1 integrin, specifically in proliferating endothelial cells. 13, 34 However, it is critical to examine ␣1(IV)NC1 effects in several well-defined relevant in vitro model culture systems before assuming that this NC1 domain is universally antiangiogenic. In this study, we examined the effects of baculovirus-expressed human ␣1(IV)NC1 protein in in vitro and in vivo models of neovascularization. We demonstrated, for the first time, that ␣1(IV)NC1 inhibits VEGFinduced MREC proliferation, migration, and tube formation through the FAK/p38-MAPK pathway. In addition, we discovered the proapoptotic effect of ␣1(IV)NC1 mediation through the regulation of antiapoptotic Bcl-x L /Bcl-2 expression and activation of caspase-3/PARP cleavage through the inhibition of p38-MAPK signaling. This finding is consistent with results of previous studies demonstrating that antiangiogenic activity of ␣1(IV)NC1 is mediated through ␣1␤1 integrin and inhibition of hypoxia-mediated signaling and apoptosis. 13, 35 ␣1(IV)NC1 inhibited the phosphorylation of FAK and p38-MAPK when MRECs were plated on type IV collagen matrix. Similarly, we previously reported that another collagen NC1 domain, ␣3(IV)NC1, inhibits the phosphorylation of FAK on fibronectin matrix. 18 Understanding the mechanism(s) of action of these molecules is crucial for their therapeutic development and use.
To further support the inhibition of angiogenesis observed in MRECs incubated with ␣1(IV)NC1 in culture, we assessed its activity in vivo. The intravenous administration of ␣1(IV)NC1 caused selective inhibition of endothelial cells growth in the VEGF-stimulated BMM, resulting in the suppression of neovascularization. Thus, ␣1(IV)NC1, which has previously been shown to suppress tumor angiogenesis in different mouse models, is also a strong antiangiogenic agent in MRECs and may be an effective therapeutic candidate for the treatment of neovascular diseases in the eye. 
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Current evidence indicates that VEGF is a major angiogenic factor and plays a prominent role in ocular neovascularization. 36 VEGF is massively upregulated by hypoxia, and its levels are increased in the retina and vitreous of patients and in animal models of ischemic retinopathy. [37] [38] [39] VEGF is responsible for the growth of new blood vessels through the stimulation of endothelial cell proliferation and migration. 36 Increased expression of VEGF in transgenic mice stimulates neovascularization within the retina, and VEGF receptor antagonists inhibit retinal and choroidal neovascularization in many animal models. 40, 41 Compared with VEGF expression, less evidence implicates basic fibroblast growth factor (FGF-2) in the development of ocular neovascularization. 42 Recently, many researchers have reported that several antiangiogenic drugs (e.g., pegaptanib sodium [Macugen; Pfizer, New York, NY], RhuFab V2 [Lucentis; Genentech, South San Francisco, CA], tryptophanyl-tRNA synthetase (TrpRS), VEGF-TRAP, AdPEDF, AG-013958, bevacizumab [Avastin; Genentech], JSM6427) inhibit ocular neovascularization and prevent leakiness of retinal blood vessels in vivo by preventing the binding of VEGF to its receptors on endothelial cells. 6, [43] [44] [45] [46] [47] [48] A known endogenous angiogenesis inhibitor, ␣2(IV)NC1 (canstatin), was recently reported to inhibit laser-induced CNV by inducing apoptosis of endothelial cells. 49 Our findings suggest that ␣1(IV)NC1 may also be effective in the inhibition of choroidal neovascularization. This is further supported by earlier findings that type IV collagen-derived NC1 domains regulate angiogenesis in a number of in vitro and in vivo models. 11 Thus, this work not only supports our efforts in the development of ␣1(IV)NC1 as a potential candidate for the treatment of ocular diseases with a neovascular component, it also supports our ongoing oncology development efforts.
